VP, Virology

Kai Lin, PhD

Kai is a virology expert with over 20 years of drug discovery and development experience in the biotech and pharmaceutical industry and has published over 40 papers on antiviral research.

Prior to joining Atea, Kai most recently served for six years as Senior Director, Head of Virology at Enanta Pharmaceuticals. Kai began his career at Vertex Pharmaceuticals where he was a key contributor to the discovery of telaprevir, the first direct-acting antiviral drug approved for the treatment of chronic hepatitis C. After Vertex, Kai spent eight years at Novartis, where he was responsible for building the first virology group and leading a number of drug candidates through the Investigational New Drug application process. Kai also served for several years as Head of Biology at Permeon Biologics and Idenix Pharmaceuticals.

Kai holds a BS from Nankai University and a PhD in biochemistry from the University of Pennsylvania.

Back to Full Team
Kai Lin, PhD